ERBB2 and neoplasm: The SK-OV-3 (HER2-positive), HCT116 (HER2-positive) or MDA-MB-231 (HER2-negative) cells were used as tumor model for the in vivo study to evaluate the antitumor efficacy of miR-HER2-E1 delivered by exosomes via intratumoral administration.